QN-165 (formerly referred to as AS1411) is a novel aptamer-based investigational drug candidate under development and evaluation with the potential to treat viral based-infectious diseases and different types of cancers. Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule and are typically created by selection from a large random sequence pool. The QN-165 aptamer is a G-rich oligonucleotide that targets and binds to nucleolin, a protein that is present on the surface of tumor cells.
Qualigen partnered with University of Louisville to exclusively develop QN-165 for inhibiting or treating COVID-19. Proof-of-concept in vitro studies demonstrate potential to protect cells from the damaging effects of SARS-CoV-2 infection. QN-165 exhibits an encouraging safety profile and GMP manufacturing for clinical trials has been secured.
The QN-165 aptamer has been tested in over 100 patients and is well tolerated with no evidence of severe side effects, with at least 7 patients having long-lasting clinical responses, where their cancers either disappeared or shrank substantially.
QN-165 is also a key component of Qualigen’s anti-nucleolin agent-conjugated nanoparticle drug candidates: QN-247, QN-247RE and QN-247CE.
QN-165 Resource Publications
- G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms (Abstract) – 2017 May
- Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation – 2015 April
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma – 2014 February
- A phase II trial of the nucleolin-targeted DNA aptamer AS1411 in metastatic refractory renal cell carcinoma – 2013 November
- In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation – 2013 March
- Oncogenic Synergism between ErbB1, Nucleolin, and Mutant Ras – 2011 March
- A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism – 2010 September
- Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML. (Abstract) – 2010 May
- A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). (Abstract) – 2010 May
- Resolution and characterization of the structural polymorphism of a single quadruplex-forming sequence – 2010 March
- Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides – 2009 December
- Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML) (Abstract) – 2009 May
- Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML) – 2009 May
- Discovery and Development of the G-rich Oligonucleotide AS1411 as a Novel Treatment for Cancer – 2009 January
- AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin – 2007 November
- Extended phase I study of AS1411 in renal and non-small cell lung cancers – 2006 June
- Extended phase I study of AS1411 in renal and non-small cell lung cancers (Abstract) – 2006 June
- AGRO100 inhibits activation of nuclear factor-KB (NF-KB) by forming a complex with NF-KB essential modulator (NEMO) and nucleolin – 2006 May
- A phase I study of AGRO100 in advanced cancer (Abstract) – 2004 July
- Biophysical and biological properties of quadruplex oligodeoxyribonucleotides – 2003 April
- Apoptosis in Leukemia Cells Is Accompanied by Alterations in the Levels and Localization of Nucleolin* – 2003 March
- Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding* – 1999 September
- AS1411: A potential targeted therapy for neuroblastoma
- Impact of AS1411 on Mechanistic Target of Rapamycin Complexes 1 and 2 (mTORC1/2) Activity